TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35878636

Group type: EXPERIMENTAL
Intervention: Endoscopic-assisted canal wall-up (EACWU) technique
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional canal wall-up (CWU) technique
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Endoscopic-assisted canal wall-up (EACWU) technique in pars tensa cholesteatoma subgroup
Number of subjects: 57

Group type: COMPARATOR
Intervention: Conventional canal wall-up (CWU) technique in pars tensa cholesteatoma subgroup
Number of subjects: 57
Study: 33547676

Group type: EXPERIMENTAL
Intervention: ubrogepant
Number of subjects: 106

Group type: COMPARATOR
Intervention: CGRP monoclonal antibody
Number of subjects: 106
Study: 34896385

Group type: EXPERIMENTAL
Intervention: Menu audit and feedback plus online menu labels
Number of subjects: 19799

Group type: COMPARATOR
Intervention: Menu audit and feedback
Number of subjects: 19799
Study: 35033011

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of PPI (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gradual tapering of PPI (Group B)
Number of subjects: 0
Study: 32669217

Group type: EXPERIMENTAL
Intervention: 6% sodium chloride (hypertonic saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.12% sodium chloride (placebo)
Number of subjects: 0
Study: 33321526

Group type: EXPERIMENTAL
Intervention: Maternal serum levels of LDL, TGs, and total cholesterol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Maternal serum triglycerides (TGs)
Number of subjects: 150
Study: 34772453

Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine health education (Control)
Number of subjects: 100
Study: 33856549

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus topical ketorolac
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bevacizumab plus artificial tears
Number of subjects: 50
Study: 33766685

Group type: EXPERIMENTAL
Intervention: Bubble technique (Group B)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Conventional technique (Group C)
Number of subjects: 260
Study: 33501601

Group type: EXPERIMENTAL
Intervention: HCB (HCD supplemented with 50 mg/kg berberine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HCD
Number of subjects: 0

Group type: COMPARATOR
Intervention: NCD
Number of subjects: 0
Study: 34533425

Group type: EXPERIMENTAL
Intervention: Clinician assistants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinicians
Number of subjects: 0
Study: 34435584

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 165

Group type: COMPARATOR
Intervention: Dupilumab 200 mg, 300 mg, 600 mg (single doses)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 33855807

Group type: EXPERIMENTAL
Intervention: Air Anatomy hand gestures
Number of subjects: 94

Group type: COMPARATOR
Intervention: Lecture on anatomy of extraocular muscles
Number of subjects: 94
Study: 33038500

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention with bi-directional texting for BP monitoring
Number of subjects: 0
Study: 36114301

Group type: EXPERIMENTAL
Intervention: Viewing children's faces
Number of subjects: 17
Study: 32314132

Group type: EXPERIMENTAL
Intervention: Reverse colocated integrated care (at least two visits with a primary care provider and at least one visit with a chronic care nurse or dietician)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Reverse colocated integrated care
Number of subjects: 416
Study: 32005093

Group type: EXPERIMENTAL
Intervention: Pain-free rehabilitation
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pain-threshold rehabilitation
Number of subjects: 43
Study: 32694286

Group type: EXPERIMENTAL
Intervention: Second generation oral contraceptives (OC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-users of oral contraceptives (non-OC)
Number of subjects: 38
Study: 33881115

Group type: EXPERIMENTAL
Intervention: Rice bran oil (30 grams per day)
Number of subjects: 40
Study: 35351035

Group type: EXPERIMENTAL
Intervention: 6-month implementation strategy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study: 33946003

Group type: EXPERIMENTAL
Intervention: Routine removal of metalwork following Lisfranc injury fixation at a median time of 6 months post fixation (interquartile range 4-10)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Reasons for removal of metalwork: to optimise physiological function and to reduce the risk of broken metalwork
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Interest in participating in a randomised controlled trial
Number of subjects: 185
Study: 36424580

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg subcutaneously daily for a mean of 18 months (range 14–24 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 40
Study: 33615336

Group type: EXPERIMENTAL
Intervention: Autologous fat grafting
Number of subjects: 13

Group type: COMPARATOR
Intervention: Offloading and activity modification
Number of subjects: 13
Study: 34314449

Group type: EXPERIMENTAL
Intervention: Eligible patients who were randomized (3,800 patients)
Number of subjects: 21818

Group type: COMPARATOR
Intervention: Eligible patients who were declined for randomization (659 patients)
Number of subjects: 21818
Study: 32024027

Group type: EXPERIMENTAL
Intervention: Sucrosomial ferric pyrophosphate plus L‐ascorbic acid (30-day oral therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 0
Study: 32327497

Group type: EXPERIMENTAL
Intervention: PEGasparaginase individualized dosing based on therapeutic drug monitoring
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PEGasparaginase during infection
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: PEGasparaginase during induction treatment
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Loading dose of PEGasparaginase
Number of subjects: 92
Study: 32070417

Group type: EXPERIMENTAL
Intervention: Web-based treatment program with therapist guidance
Number of subjects: 303

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 303
Study: 34299733

Group type: EXPERIMENTAL
Intervention: Studies using placebos
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Double-blind studies
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Triple-blind studies
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Crossover design studies
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Overall studies
Number of subjects: 2565

Group type: EXPERIMENTAL
Intervention: Performance bias
Number of subjects: 2565
Study: 32320457

Group type: EXPERIMENTAL
Intervention: HIV self-testing kits distribution (intervention group)
Number of subjects: 400
Study: 35789991

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU monthly for 5 years)
Number of subjects: 20334
Study: 33785488

Group type: EXPERIMENTAL
Intervention: Mobile serious game ReValidate!
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard care (unsupervised exercises and referral for physiotherapy or exercise therapy upon request)
Number of subjects: 92
Study: 35710440

Group type: EXPERIMENTAL
Intervention: Clindamycin capsules for 10 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 80
Study: 35241469

Group type: EXPERIMENTAL
Intervention: Palbociclib in combination with an aromatase inhibitor (AI)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Palbociclib in combination with fulvestrant
Number of subjects: 1000
Study: 33385198

Group type: EXPERIMENTAL
Intervention: Hook-eye front-closure bra
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zipper front-closure bra
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hook-loop front-closure bra
Number of subjects: 60
Study: 33587402

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 32589632

Group type: EXPERIMENTAL
Intervention: Household Treatment group (all family members treated)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Individual Treatment group (only affected participants treated)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Household Treatment group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Individual Treatment group
Number of subjects: 79
Study: 36038262

Group type: EXPERIMENTAL
Intervention: Treg infusions (1 × 10^6 cells/kg) IV every 4 weeks and IL-2 (2 × 10^5 IU/m2) injections 3 times/week
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Treg infusions (2 × 10^6 cells/kg and 3 × 10^6 cells/kg) in OLE
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Treg/IL-2 treatments
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 33818395

Group type: EXPERIMENTAL
Intervention: Treatment app (including pelvic floor muscle training, bladder training, psychoeducation, lifestyle advice, tailored advice, exercise log, reinforcement messages, and reminders)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Treatment app
Number of subjects: 123

Group type: COMPARATOR
Intervention: Information app (control group)
Number of subjects: 123
Study: 36476386

Group type: EXPERIMENTAL
Intervention: Online behavior change intervention with weekly individual online sessions for 12 weeks and an activity monitor
Number of subjects: 46

Group type: COMPARATOR
Intervention: Online educational program (1 hour)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Weekly individual online sessions for 12 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Activity monitor with specific strategies
Number of subjects: 46
Study: 33548765

Group type: EXPERIMENTAL
Intervention: Lumbar rotation with extension subgroup
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Lumbar rotation subgroup
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Gender × test interaction
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Subgroup × test interaction
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Subgroup × gender interaction
Number of subjects: 154
Study: 35452654

Group type: EXPERIMENTAL
Intervention: Measurement of the angle of progression in addition to digital examination
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (digital examination only)
Number of subjects: 45
Study: 33617184

Group type: EXPERIMENTAL
Intervention: 2D model
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: 2D-CDFI model
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: 2D-CDFI-PW model
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: CNN classifications
Number of subjects: 3623

Group type: EXPERIMENTAL
Intervention: 2D model (size comparison)
Number of subjects: 3623
Study: 32004437

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1% 4 times a day for four weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1% 3 times a day for three weeks
Number of subjects: 64
Study: 35172054

Group type: EXPERIMENTAL
Intervention: Nirmatrelvir plus ritonavir
Number of subjects: 2246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2246
Study: 34117190

Group type: EXPERIMENTAL
Intervention: Educational intervention addressing living with a PCN tube, provided twice (before placement and at first tube change, 6 weeks later)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard instruction (control group)
Number of subjects: 178
Study: 32049772

Group type: EXPERIMENTAL
Intervention: Pediatric HIV disclosure intervention
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 446
Study: 35022779

Group type: EXPERIMENTAL
Intervention: COVID-19-directed therapies
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Systemic steroids
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 424
Study: 35724261

Group type: EXPERIMENTAL
Intervention: Reduced mobility
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Family history of deep vein thrombosis
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Catheterization of veins on the back of the hand
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Pain
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate
Number of subjects: 1319

Group type: EXPERIMENTAL
Intervention: Omeprazole Sodium
Number of subjects: 1319
Study: 34470831

Group type: EXPERIMENTAL
Intervention: Iron sucrose (100 mg biweekly, total 2 grams)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ferric carboxymaltose (500 mg every 10 weeks, total 2 grams)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Ferric carboxymaltose
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Erythropoiesis stimulating agent dosing
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 142
Study: 32664946

Group type: EXPERIMENTAL
Intervention: 12-month structured exercise training (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-of-care for detecting cardiac dysfunction (resting left-ventricular ejection fraction assessed from 3-dimensional echocardiography)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care control group (n=50)
Number of subjects: 100
Study: 35555966

Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone acetonide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fractional CO2 laser therapy followed by topical application of the drug for six sessions
Number of subjects: 36
Study: 33059771

Group type: EXPERIMENTAL
Intervention: Adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac, 3 μg/0.5 mL (600 SU per dose), two doses IM with a two-week interval.
Number of subjects: 13060

Group type: COMPARATOR
Intervention: Placebo containing aluminium hydroxide in a 0.5 mL solution, two doses IM with a two-week interval.
Number of subjects: 13060
Study: 35304977

Group type: EXPERIMENTAL
Intervention: Coadministration of 200 mg cyclosporine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Coadministration of 600 mg quinidine
Number of subjects: 27
Study: 32265508

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 33687763

Group type: EXPERIMENTAL
Intervention: Atezolizumab with etoposide and carboplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Durvalumab with etoposide and either cisplatin or carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone (etoposide and carboplatin or cisplatin)
Number of subjects: 0
Study: 33356487

Group type: EXPERIMENTAL
Intervention: ACT+SSRI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ERP+SSRI
Number of subjects: 40

Group type: COMPARATOR
Intervention: SSRI-only
Number of subjects: 40
Study: 32884939

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting cancer-specific survival (CSS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calibration curve of the nomogram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision curve analyses (DCAs)
Number of subjects: 0
Study: 36471257

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 774

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 774

Group type: COMPARATOR
Intervention: Postoperative adjuvant therapy (no therapy)
Number of subjects: 774
Study: 33773120

Group type: EXPERIMENTAL
Intervention: Riociguat (up to 2.5 mg three times per day)
Number of subjects: 226

Group type: COMPARATOR
Intervention: PDE5i (oral sildenafil [≥60 mg per day] or oral tadalafil [20–40 mg per day])
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 226

Group type: COMPARATOR
Intervention: PDE5i
Number of subjects: 226
Study: 32546647

Group type: EXPERIMENTAL
Intervention: Immune checkpoint blockade (ICB) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: IDO enzyme inhibitor treatment
Number of subjects: 0
Study: 35991780

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled (PC) ventilation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volume-Controlled (VC) ventilation
Number of subjects: 40
Study: 33580944

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (30 mg/kg, six doses each 5 mg/kg, biweekly for 3 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Miltefosine (2.5 mg/kg or 100 mg/day for 12 weeks)
Number of subjects: 100
Study: 35112516

Group type: EXPERIMENTAL
Intervention: Salt and date palm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 32282034

Group type: COMPARATOR
Intervention: Telephone support
Number of subjects: 1155

Group type: COMPARATOR
Intervention: SMS support
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1155
Study: 35925752

Group type: EXPERIMENTAL
Intervention: 5:2 fasting diet
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1.8 mg/day liraglutide
Number of subjects: 61
Study: 32012966

Group type: EXPERIMENTAL
Intervention: Individual Home Training (IHT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gym Group Training (GGT)
Number of subjects: 0
Study: 32391744

Group type: EXPERIMENTAL
Intervention: Somatosensory impairment recovery (measured by EmNSA-UE)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Motor recovery (measured by FM-UE)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Time progression
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Severe somatosensory impairment at baseline
Number of subjects: 94
Study: 36375318

Group type: EXPERIMENTAL
Intervention: Power visual-motor illusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard visual-motor illusion
Number of subjects: 20
Study: 32893049

Group type: EXPERIMENTAL
Intervention: FERM/scGOS/lcFOS
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: FERM
Number of subjects: 350
Study: 32828393

Group type: EXPERIMENTAL
Intervention: Biotin supplementation at 0.3 mg/L (T1) and 0.45 mg/L (T2) in drinking water for older hens (53-56 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No biotin (T0)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Biotin supplementation (T1 and T2)
Number of subjects: 120
Study: 35986471

Group type: EXPERIMENTAL
Intervention: MTA with 2% Chlorhexidine Gluconate (CHX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: MTA alone
Number of subjects: 40
Study: 33600105

Group type: EXPERIMENTAL
Intervention: 25° semisitting position
Number of subjects: 38

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 38
Study: 32092343

Group type: EXPERIMENTAL
Intervention: 18 months androgen suppression (AS)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: High-dose-rate brachytherapy boost (HDRB)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: 66 Gy external beam radiation therapy (EBRT)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: 70 Gy external beam radiation therapy (EBRT)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: 74 Gy external beam radiation therapy (EBRT)
Number of subjects: 1051

Group type: COMPARATOR
Intervention: 46 Gy EBRT plus HDRB
Number of subjects: 1051
Study: 36128557

Group type: EXPERIMENTAL
Intervention: Trusilk R
Number of subjects: 129

Group type: COMPARATOR
Intervention: Mersilk R
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Trusilk R and Mersilk R
Number of subjects: 129
Study: 32220252

Group type: COMPARATOR
Intervention: Telephone intervention with 30 days of continuous phone support and two scheduled phone calls after discharge.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving usual care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone intervention.
Number of subjects: 0
Study: 33550619

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 96

Group type: COMPARATOR
Intervention: Tamsulosin
Number of subjects: 96
Study: 32030911

Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention (LI)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 210
Study: 36184124

Group type: EXPERIMENTAL
Intervention: Carotegrast methyl 480 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carotegrast methyl 960 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Carotegrast methyl (concentration-response analysis)
Number of subjects: 48
Study: 33131460

Group type: EXPERIMENTAL
Intervention: CMJ performed at 60°
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CMJpref
Number of subjects: 16

Group type: COMPARATOR
Intervention: CMJrefer
Number of subjects: 16
Study: 32797382

Group type: EXPERIMENTAL
Intervention: Universal HIV testing and treatment (UTT) including home-based and mobile testing, active linkage to care, rapid ART start, and enhanced male circumcision services.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Universal HIV testing and treatment (UTT)
Number of subjects: 30
Study: 34002974

Group type: EXPERIMENTAL
Intervention: 30-second static hamstring muscle stretch
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 60-second static hamstring muscle stretch
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (sham stretch for 20 seconds)
Number of subjects: 100
Study: 32536075

Group type: EXPERIMENTAL
Intervention: Quality of Professional Life Scale of Nurses
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Self Rating Depression Scale
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 242
Study: 35997234

Group type: EXPERIMENTAL
Intervention: L-menthol ingestion (M-IG)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: L-menthol mouth rinsing (M-MR)
Number of subjects: 13
Study: 34274407

Group type: EXPERIMENTAL
Intervention: G/M (3 months glargine followed by 9 months metformin)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: MET (12 months metformin)
Number of subjects: 221
Study: 32192644

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 or 150 mg every 2 weeks)
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 281